184 related articles for article (PubMed ID: 9516596)
1. Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
Gianni L
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):13-5. PubMed ID: 9516596
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
5. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
6. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
Paridaens R
Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Serra P; Tienghi A; Ravaioli A; Gentile A; Salzano E
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):30-3. PubMed ID: 9144688
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Lück HJ; Thomssen C; Du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):36-9. PubMed ID: 9516602
[TBL] [Abstract][Full Text] [Related]
11. Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer.
Gianni L; Capri G
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S1-3. PubMed ID: 9071331
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
15. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
[TBL] [Abstract][Full Text] [Related]
19. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
20. Future developments for paclitaxel in the treatment of breast cancer.
Bonadonna G
Semin Oncol; 1996 Feb; 23(1 Suppl 1):65-8. PubMed ID: 8629041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]